Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 525

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 525
---
 and SP the Company’s estimate of future potential product returns is based on the on-handchannel inventory data and sell-through data obtained from the SDs and SP. In arriving at its estimate, the Company also considers historical product returns, the underlying product demand, and industry data specific to the specialty pharmaceutical distribution industry. The total amount deducted from gross product sales for the allowances described above for the three months ended September 30, 2024, and 2023, was $1.7 million and $1.3 million, respectively, and for the nine months ended September 30, 2024 and 2023 was $4.7 million and $3.4 million, respectively. The following table sets forth the changes in the accrued revenue allowances (in thousands):

|                                    |     | 2024 | Three Months Ended 
      September 30, |   |     | 2023 |       |   |     | 2024 | Nine Months Ended 
     September 30, |   |     | 2023 |        |   |
|:-----------------------------------|:----|:-----|-------------------:|:--|:----|:-----|------:|:--|:----|:-----|------------------:|:--|:----|:-----|-------:|:--|
| Balance at beginning of period     |     | $    |              1,289 |   |     | $    | 1,927 |   |     | $    |             1,065 |   |     | $    |  1,434 |   |
| Provision for current period sales |     |      |              1,710 |   |     |      | 1,269 |   |     |      |             4,695 |   |     |      |  3,399 |   |
| Payments                           |     |      |             (1,894 | ) |     |      |  (550 | ) |     |      |            (4,655 | ) |     |      | (2,187 | ) |
| Balance at end of period           |     | $    |              1,105 |   |     | $    | 2,646 |   |     | $    |             1,105 |   |     | $    |  2,646 |   |

Research and Development Research and development expenses consist of costs incurred in performing research and development activities, including salaries and